{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Recovery News | Mental Health & Addiction Recovery","title":"Two Infusions, Twelve Weeks: An Experimental Treatment Holds Binge Eating at Bay in Six People","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/b7fe5dc9\"></iframe>","width":"100%","height":180,"duration":206,"description":"Two Infusions, Twelve Weeks: An Experimental Treatment Holds Binge Eating at Bay in Six People\nBioPharmaDispatch reported Entropy Therapeutics' 12-week Cohort 1 results for TRP-8803, an infused psilocin compound: all six patients with treatment-resistant binge eating disorder maintained clinically meaningful improvement, weekly episodes stayed 73% below baseline, and three had no binges at all — very early, small, company-reported data for an unapproved, investigational treatment.\nSource\nEntropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends — BioPharmaDispatch, November 2026, reporting Entropy Therapeutics / Swinburne University of Technology","thumbnail_url":"https://img.transistorcdn.com/1HMwgudOv-9iLP25S2rFy3To1lXT_m4L2ceV1SNYp_k/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83NWQ4/NzUyZmIxMzg4YjVk/YzI2NWVkOGVkYmQ0/NzBkOC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}